COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

An Exploratory Study of NBI-34060 Capsules and Next Day Functioning

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00525941
Recruitment Status : Withdrawn (Study discontinued due to Approvable decision)
First Posted : September 6, 2007
Last Update Posted : May 12, 2015
Information provided by:
Neurocrine Biosciences

Brief Summary:
NBI-34060 is an investigational (research) medication being studied in people with insomnia. The current study is designed to evaluate how people, who experience a nighttime awakening with difficulty returning to sleep, feel during the next day after dosing with NBI-34060. The study will also examine the pattern and extent of nighttime awakenings as reported by the patients, as well as and the patient's sleep experience during treatment.

Condition or disease Intervention/treatment Phase
Insomnia Drug: NBI-34060 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: An Exploratory Phase IIIb, Single-Blind, Outpatient Study to Assess Next-Day Functioning in Adult Primary Insomnia Patients Following the Administration of NBI-34060 Capsules During the Night
Study Start Date : September 2007
Actual Primary Completion Date : January 2008
Actual Study Completion Date : January 2008

Intervention Details:
  • Drug: NBI-34060
    10 mg capsules; dosed as needed for falling back asleep after a bothersome awakening provided there are at least 4 hours remaining in bed; no more than one dose per night.

Primary Outcome Measures :
  1. Assessments of Next-Day Function [ Time Frame: daily/six weeks ]

Secondary Outcome Measures :
  1. Quality of Life [ Time Frame: biweekly/six weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • insomnia (DSM-IV diagnosed; at least one month)
  • Nocturnal awakenings
  • Usual bedtimes between 9:00PM and Midnight.
  • Bedtimes that do not vary by more than 2 hours on 5 or more nights per week.
  • A usual time in bed of 7 to 9 hours.

Exclusion Criteria:

  • no serious concomitant illness
  • no other condition that could interfere with sleep

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00525941

Layout table for location information
United States, Georgia
Sleep Disorders Center of Georgia
Atlanta, Georgia, United States, 30342
United States, New York
Clinilabs, Inc.
New York, New York, United States, 10019
United States, Ohio
Community Research
Cincinnati, Ohio, United States, 45227
Tri-State Sleep Disorders Center
Cincinnati, Ohio, United States, 45246
Sponsors and Collaborators
Neurocrine Biosciences
Layout table for investigator information
Principal Investigator: Gary K. Zammit, PhD Clinilabs, Inc.
Layout table for additonal information
Responsible Party: Christopher O'Brien, Chief Medical Officer, Neurocrine Biosciences, Inc. Identifier: NCT00525941    
Other Study ID Numbers: NBI-34060-IR-0702
First Posted: September 6, 2007    Key Record Dates
Last Update Posted: May 12, 2015
Last Verified: April 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Initiation and Maintenance Disorders
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action